Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.
Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, Martignoni ME, Werner A, Hein R, H Busch D, Peschel C, Rad R, Cox J, Mann M, Krackhardt AM. Bassani-Sternberg M, et al. Nat Commun. 2016 Nov 21;7:13404. doi: 10.1038/ncomms13404. Nat Commun. 2016. PMID: 27869121 Free PMC article.
Mass-spectrometry-based draft of the human proteome.
Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, Ziegler E, Butzmann L, Gessulat S, Marx H, Mathieson T, Lemeer S, Schnatbaum K, Reimer U, Wenschuh H, Mollenhauer M, Slotta-Huspenina J, Boese JH, Bantscheff M, Gerstmair A, Faerber F, Kuster B. Wilhelm M, et al. Nature. 2014 May 29;509(7502):582-7. doi: 10.1038/nature13319. Nature. 2014. PMID: 24870543
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia.
Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, Slotta-Huspenina J, Steiger K, Altmann T, Weißer T, Steidle S, Schick M, Jacobs L, Slawska J, Müller-Thomas C, Verbeek M, Subklewe M, Peschel C, Wester HJ, Schwaiger M, Götze K, Keller U. Herhaus P, et al. Haematologica. 2016 Aug;101(8):932-40. doi: 10.3324/haematol.2016.142976. Epub 2016 May 12. Haematologica. 2016. PMID: 27175029 Free PMC article.
RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells.
Höckendorf U, Yabal M, Herold T, Munkhbaatar E, Rott S, Jilg S, Kauschinger J, Magnani G, Reisinger F, Heuser M, Kreipe H, Sotlar K, Engleitner T, Rad R, Weichert W, Peschel C, Ruland J, Heikenwalder M, Spiekermann K, Slotta-Huspenina J, Groß O, Jost PJ. Höckendorf U, et al. Cancer Cell. 2016 Jul 11;30(1):75-91. doi: 10.1016/j.ccell.2016.06.002. Cancer Cell. 2016. PMID: 27411587 Free article.
A Novel Grading System Based on Tumor Budding and Cell Nest Size Is a Strong Predictor of Patient Outcome in Esophageal Squamous Cell Carcinoma.
Jesinghaus M, Boxberg M, Konukiewitz B, Slotta-Huspenina J, Schlitter AM, Steiger K, Specht K, Wieczorek K, Warth A, Schmidt T, Hartmann A, Demir IE, Feith M, Ott K, Weichert W. Jesinghaus M, et al. Am J Surg Pathol. 2017 Aug;41(8):1112-1120. doi: 10.1097/PAS.0000000000000865. Am J Surg Pathol. 2017. PMID: 28505009
Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Jesinghaus M, Steiger K, Slotta-Huspenina J, Drecoll E, Pfarr N, Meyer P, Konukiewitz B, Bettstetter M, Wieczorek K, Ott K, Feith M, Langer R, Weichert W, Specht K, Boxberg M. Jesinghaus M, et al. Oncotarget. 2017 Jul 18;8(29):46756-46768. doi: 10.18632/oncotarget.18606. Oncotarget. 2017. PMID: 28657901 Free PMC article.
A20 deletion in T cells modulates acute graft-versus-host disease in mice.
Fischer JC, Otten V, Steiger K, Schmickl M, Slotta-Huspenina J, Beyaert R, van Loo G, Peschel C, Poeck H, Haas T, Spoerl S. Fischer JC, et al. Eur J Immunol. 2017 Nov;47(11):1982-1988. doi: 10.1002/eji.201646911. Epub 2017 Sep 15. Eur J Immunol. 2017. PMID: 28833031 Free article.
Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.
Reidel V, Kauschinger J, Hauch RT, Müller-Thomas C, Nadarajah N, Burgkart R, Schmidt B, Hempel D, Jacob A, Slotta-Huspenina J, Höckendorf U, Peschel C, Kern W, Haferlach T, Götze KS, Jilg S, Jost PJ. Reidel V, et al. Oncotarget. 2018 Apr 3;9(25):17270-17281. doi: 10.18632/oncotarget.24775. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707107 Free PMC article.
167 results